Liraglutide vs Pelargonium Sidoides

Q: Is Liraglutide better than Pelargonium Sidoides?

Liraglutide has a higher evidence score (7.5/10 vs 6.5/10) and wins in 2 of 3 categories.

Q: Can I take Liraglutide and Pelargonium Sidoides together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.

Head-to-head evidence comparison — which supplement is right for you?

Quick answerNo interaction data — ask a pharmacist

Liraglutide vs Pelargonium Sidoides: Liraglutide has the stronger overall evidence (7.5 vs 6.5/10); the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.

Liraglutide Edges Ahead

Liraglutide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.

Liraglutide2 wins

Pelargonium Sidoides1 win

Which is right for you? Take the 60-second quiz Open in the full comparison tool

Lir7.5

Liraglutide

Too few graded studiesLimited safety

Pel6.5

Pelargonium Sidoides

Too few graded studiesModerate safety

Evidence

Evidence Score

Best7.5/10

Studies: 436

Meta-analyses: 73

Level: Strong

Evidence Score

6.5/10

Studies: 35

Meta-analyses: 2

Level: Moderate

Research findings

Verdict

Too few graded studies

Top outcomes

Blood sugar & glycemic controlToo few graded studies242
Weight managementToo few graded studies124
Cardiovascular outcomesToo few graded studies42

Verdict

Too few graded studies

Top outcomes

Immune supportToo few graded studies5
Safety profileToo few graded studies1

Dosage & timing

Recommended Dosage:

Prescription-only, clinician-titrated, subcutaneous once daily. Diabetes (Victoza): escalate 0.6 → 1.2 → 1.8 mg/day. Weight management (Saxenda): escalate weekly to 3.0 mg/day. DO NOT self-dose.

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication.
US FDA labeling includes a boxed warning about thyroid C-cell tumors: liraglutide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.
Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.
Risk of gallbladder disease (gallstones, cholecystitis), particularly with rapid weight loss.
Gastrointestinal adverse effects (nausea, vomiting, diarrhea) are very common, especially during dose escalation.
Weight loss includes loss of lean muscle mass — pair with resistance training and adequate protein.
FDA has warned about COMPOUNDED / grey-market GLP-1 products: risk of dosing errors, impurities, and unapproved salt forms. Use only pharmacy-dispensed product.
Not for cosmetic weight loss without a genuine medical indication.
May increase hypoglycemia risk when combined with insulin or sulfonylureas (dose adjustment needed).

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Subcutaneous once-daily injection (Victoza for diabetes, Saxenda for weight)

Recommended Dosage:

Liquid EPs 7630: 30 drops three times daily for adults during an acute infection (the cited trials used this dose in 12 to 18 year olds, and gave adults 30, 60 or 90 mg of EPs 7630 a day as tablets)

Warnings

Evidence quality for efficacy is low to very low per the Cochrane review
Rare reports of hepatotoxicity have prompted regulatory cautions
Adverse events (mostly GI) were more frequent than placebo in trials

Best Time:

Spread through the day

Can take on empty stomach

Best Form:

Liquid extract (EPs 7630)

Safety

Limited safety

Drug Interactions:

Other GLP-1 receptor agonists (severe)
Insulin and sulfonylureas (moderate)
Oral medications (general) (moderate)

Side Effects:

NauseaVomiting / diarrhea / constipationGallbladder disease (cholelithiasis / cholecystitis)

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC) (a contraindication under the US label)
Multiple Endocrine Neoplasia syndrome type 2 (MEN2) (a contraindication under the US label)

Moderate safetyBest

Drug Interactions:

Anticoagulants / antiplatelets (e.g. warfarin) (moderate)

Side Effects:

Mild GI upset (nausea, diarrhea, stomach pain)Allergic skin reactionsRare hepatotoxicity (case reports)

Contraindications:

Known liver disease (rare hepatotoxicity reports)
Bleeding disorders or anticoagulant use (theoretical)

What you'll notice

🩸 Improved glycemic controlpositive

Weeks to months

⚖️ Moderate weight losspositive

Months (titrated over weeks)

❤️ Reduced cardiovascular eventspositive

Months to years

🤢 GI adverse effects (very common)trade-off

Especially during dose escalation

🫁 Faster acute-bronchitis recoverypositive

Days 4-7 of an acute episode

🤧 Reduced cold / URTI symptom durationpositive

Within the acute illness window

⚠️ More adverse events than placebonegative

During use

Key studies

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER).

N Engl J Med (2016) · Rct · n=9340

Double-blind cardiovascular-outcomes RCT: 9,340 patients with type 2 diabetes and high cardiovascular risk, liraglutide or placebo added to standard care, median follow-up 3.8 years.

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes).

N Engl J Med (2015) · Rct · n=3731

56-week double-blind RCT in 3,731 adults WITHOUT type 2 diabetes (BMI ≥30, or ≥27 with comorbidities), liraglutide 3.0 mg/day vs placebo plus lifestyle (2:1)

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.

JAMA (2015) · Rct · n=846

56-week double-blind RCT in 846 adults with overweight or obesity and type 2 diabetes, liraglutide 3.0 mg, 1.8 mg or placebo (2:1:1), all with diet and activity advice.

All Liraglutide studies

Pelargonium sidoides extract for treating acute respiratory tract infections.

Cochrane Database Syst Rev (2013) · Systematic review · n=10 trials; ~746 adults and ~819 children

Liquid EPs 7630 showed effectiveness for acute bronchitis in both adults and children; tablets did not

Treatment of acute bronchitis with EPs 7630: randomized, controlled trial in children and adolescents.

Pediatr Int (2012) · Rct · n=220 children/adolescents

Significantly greater BSS reduction with EPs 7630 versus placebo (P<0.0001)

Efficacy and tolerability of EPs 7630 tablets in patients with acute bronchitis: a randomised, double-blind, placebo-controlled dose-finding study with a herbal drug preparation from Pelargonium sidoides.

Wien Med Wochenschr (2010) · Rct · n=406 adults

All three active dose groups improved patient-reported outcomes versus placebo at day 7

All Pelargonium Sidoides studies

Frequently asked questions

Is Liraglutide better than Pelargonium Sidoides?

Liraglutide has a higher evidence score (7.5/10 vs 6.5/10) and wins in 2 of 3 categories.

Can I take Liraglutide and Pelargonium Sidoides together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.

Related comparisons

Liraglutide vs Semaglutide Liraglutide vs Tirzepatide AREDS2 Formula vs Liraglutide Dulaglutide vs Liraglutide Pelargonium Sidoides vs Tirzepatide Pelargonium Sidoides vs Thiamine

Still deciding between Liraglutide and Pelargonium Sidoides?

The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.

Get your personalised pick Liraglutide details Pelargonium Sidoides details

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication.

US FDA labeling includes a boxed warning about thyroid C-cell tumors: liraglutide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.

Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.

Risk of gallbladder disease (gallstones, cholecystitis), particularly with rapid weight loss.

Gastrointestinal adverse effects (nausea, vomiting, diarrhea) are very common, especially during dose escalation.

Weight loss includes loss of lean muscle mass — pair with resistance training and adequate protein.

FDA has warned about COMPOUNDED / grey-market GLP-1 products: risk of dosing errors, impurities, and unapproved salt forms. Use only pharmacy-dispensed product.

Not for cosmetic weight loss without a genuine medical indication.

May increase hypoglycemia risk when combined with insulin or sulfonylureas (dose adjustment needed).

Frequently asked questions

Is Liraglutide better than Pelargonium Sidoides?

Liraglutide has a higher evidence score (7.5/10 vs 6.5/10) and wins in 2 of 3 categories.

Can I take Liraglutide and Pelargonium Sidoides together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.